Biomni AI for Biomedical Research скачать в хорошем качестве

Biomni AI for Biomedical Research

a16z Leads $13.5M Seed Round for Phylo's AI Agent "Biomni", Adopted by 7,000+ Labs Report: Phylo, a startup founded by recent Stanford PhDs Kexin Huang and Yuanhao Qu, has secured $13.5M in seed funding. The round was co-led by Andreessen Horowitz (a16z) and Menlo Ventures' Anthology Fund, which collaborates with Anthropic. The investment centers on Phylo's flagship product: Biomni, an open-source AI agent designed to revolutionize how biologists interact with computational tools. Biomni aims to function as an "Integrated Development Environment (IDE) for Biology." It tackles a major pain point: the fragmentation of biological data across PDFs, spreadsheets, scripts, and databases. Biomni's architecture combines a unified "action space" of over 300 validated biological tools, software packages, and databases (Biomni-E1) with a general-purpose AI agent (Biomni-A1) that executes complex research workflows based on natural language queries. The system has demonstrated significant utility. In one case, it autonomously analyzed months of wearable device data in 35 minutes—a task estimated to take three weeks manually. It has also successfully designed and executed complex molecular cloning protocols and single-cell multi-omics analyses, matching the performance of experienced researchers in some tasks. Since its open-source release less than a year ago, Biomni has been adopted by over 7,000 laboratories, including 18 of the top 20 global pharmaceutical companies. Phylo plans to monetize through Biomni Lab, an enterprise version offering enhanced security and custom agent support. Founder Kexin Huang, whose prior AI research in drug repurposing and gene effect prediction faced adoption barriers, believes AI agents like Biomni are key to bridging the gap between powerful models and practical use. The long-term vision is for such platforms to become the primary workspace for biologists, automating routine tasks and allowing scientists to focus on high-level discovery. The company is backed by a strong scientific advisory board including Nobel laureate Carolyn Bertozzi and CRISPR pioneers Feng Zhang and Le Cong. https://phylo.bio/ https://biomni.stanford.edu/paper.pdf